Lyra Therapeutics (LYRA) Competitors

Plus Therapeutics (NASDAQ:PSTV) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Which has higher earnings and valuation, PSTV or LYRA?

Plus Therapeutics has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.82M	8.36	-$12.98M	-$2.24	-0.22
Lyra Therapeutics	$770K	15.06	-$93.43M	-$29.01	-0.24

Is PSTV or LYRA more profitable?

Plus Therapeutics has a net margin of -357.85% compared to Lyra Therapeutics' net margin of -5,043.64%. Plus Therapeutics' return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-357.85%	N/A	-117.72%
Lyra Therapeutics	-5,043.64%	-404.56%	-60.06%

Which has more volatility & risk, PSTV or LYRA?

Plus Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.

Does the media prefer PSTV or LYRA?

In the previous week, Plus Therapeutics had 4 more articles in the media than Lyra Therapeutics. MarketBeat recorded 6 mentions for Plus Therapeutics and 2 mentions for Lyra Therapeutics. Plus Therapeutics' average media sentiment score of 1.19 beat Lyra Therapeutics' score of 0.87 indicating that Plus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate PSTV or LYRA?

Plus Therapeutics presently has a consensus price target of $8.88, indicating a potential upside of 1,711.22%. Lyra Therapeutics has a consensus price target of $100.00, indicating a potential upside of 1,318.44%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Lyra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do insiders and institutionals have more ownership in PSTV or LYRA?

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 0.8% of Plus Therapeutics shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Plus Therapeutics beats Lyra Therapeutics on 12 of the 16 factors compared between the two stocks.